<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03794037</url>
  </required_header>
  <id_info>
    <org_study_id>Hawaa-5</org_study_id>
    <nct_id>NCT03794037</nct_id>
  </id_info>
  <brief_title>Montelukast for Prevention &amp; Treatment of OHSS</brief_title>
  <official_title>Montelukast for Prevention &amp; Treatment of Ovarian Hyperstimulation Syndrome in Freeze-all Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hawaa Fertility Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      montelukast &amp; dydrgesteron will be given to cases with suspected or proven ovarian
      hyperstimulation in one group in comparison with dydrogesteron alone in the other group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patients with high risk for ovarian hyperstimulation will undergo a freeze-all protocol then
      montelukast &amp; dydrgesteron will be given to cases with suspected or proven ovarian
      hyperstimulation in one group in comparison with dydrogesteron alone in the other group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants who develop ovarian hyperstimulation syndrome</measure>
    <time_frame>0-14 days</time_frame>
    <description>incidence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants treated of ovarian hyperstimulation syndrome</measure>
    <time_frame>0-14 days</time_frame>
    <description>treatment &amp; resolution</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dydrgesterone 10 mg( tab)/12hs/14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dydrgesterone 10 mg( tab)/12hs/14 days</intervention_name>
    <description>Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup</description>
    <arm_group_label>control</arm_group_label>
    <other_name>progesterone only</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days</intervention_name>
    <description>montelukast 10 mg(tab) once daily oral for 7 days &amp; dydrgesterone 10 mg (tab) twice daily oral for 14 days &amp;</description>
    <arm_group_label>study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOS high responders high numbers of ovum retrieved

        Exclusion Criteria:

          -  hypersensitivity to any drug components phenylketonuria patients depression liver
             dysfunction
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>infertile females undergoing ART cycles</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ahmed sa saad, MD, ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hawaa Fertility Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ahmed sa saad, MD, ph D</last_name>
    <phone>02001221709989</phone>
    <email>drahmedsaad@live.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banha University- Hawaa Fertility center</name>
      <address>
        <city>Banha</city>
        <state>Qalyubiya</state>
        <zip>13512</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed sa saad, MD, ph D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 2, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>October 12, 2019</last_update_submitted>
  <last_update_submitted_qc>October 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Ahmed Saad</investigator_full_name>
    <investigator_title>Assistant professor of Ob. &amp; Gyn.</investigator_title>
  </responsible_party>
  <keyword>ovarian hyperstimulation syndrome</keyword>
  <keyword>Montelukast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>study protocol, results,statistics</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>6 months</ipd_time_frame>
    <ipd_access_criteria>drahmedsaad@live.com</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

